The biggest questions hanging over pharma in 2024

Key trends on the horizon in the life sciences this year.

By Meagan Parrish • Jan. 25, 2024

Breast cancer tops list of most studied diseases

The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.

By Kelly Bilodeau • Jan. 24, 2024

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

Controversial challenge trials offer unparalleled innovation — with ethical bumps

Demand for infectious disease treatments is projected to grow and challenge trials, when done right, could speed drug development.

By Kelly Bilodeau • Jan. 22, 2024

The hunt for an elusive universal coronavirus vaccine

A new study shows that a universal vaccine would lead to huge financial and mortality wins during a pandemic, but development has been slow going.

By Alexandra Pecci • Jan. 22, 2024

Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention

Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.

By Meagan Parrish • Jan. 19, 2024

Pharma takes a gut check of microbiome drugs

On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.

By Kelly Bilodeau • Jan. 16, 2024

Pharma execs sound off on trends and policies they’re tracking in 2024

From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.

By Meagan Parrish • Jan. 12, 2024

PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials

As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.

By Meagan Parrish • Jan. 11, 2024

Believe the hype? Mixed signals from AI’s impact on drug development

Although AI’s failure rates in drug development still leave room for improvement, today’s missteps feed tomorrow’s successes.

By Kelly Bilodeau • Jan. 10, 2024

PharmaVoice’s Crystal Ball: Perspectives on the financial future

Industry leaders predict what it will take for pharma to defeat its financial foes in 2024.

By Meagan Parrish • Jan. 9, 2024

Regulatory twists and turns are coming for biopharma in 2024

New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.

By Kelly Bilodeau • Jan. 8, 2024

In the post-pandemic era, three players still dominate the infectious disease market

While key companies maintain their grip on the space, emerging infectious disease focus areas and a handful of other players are augmenting the market.

By Alexandra Pecci • Jan. 5, 2024

Alzheimer’s research is hot, but successful patient recruitment will determine its future

Key strategies for bringing more patients into the clinical trial fold.

By Kelly Bilodeau • Jan. 4, 2024

10 of our most read articles in 2023

A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.

By Meagan Parrish • Dec. 22, 2023

As ALS research booms, one treatment center finds itself in the spotlight

The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.

By Jacob Bell • Dec. 22, 2023

This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain

Arbor Biotechnologies is looking past CRISPR’s recent regulatory wins and into the next stage of gene editing.

By Michael Gibney • Dec. 19, 2023

5 noteworthy pharma AI investments in 2023

The last year showed how some of the world’s biggest pharma companies are leveraging AI tech.

By Alexandra Pecci • Dec. 19, 2023

Babson gets one step closer to delivering on Theranos-like blood testing

A recent FDA clearance could pave the way to pin-prick blood tests at local pharmacies and potentially one day, clinical trials.

By Kelly Bilodeau • Dec. 18, 2023

Rise of the chief investment officer: Why the unique role works for Roivant

Dr. Mayukh Sukhatme, president and chief investment officer for Roivant, discusses the long game of partnering and business deals in biopharma.

By Alexandra Pecci • Dec. 18, 2023

The many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them

Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong.

By Michael Gibney • Dec. 14, 2023

A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19

Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.

By Meagan Parrish • Dec. 13, 2023

What’s being done to prepare for the next pandemic?

Will the world be ready when a new outbreak hits? Here’s a look at the efforts to combat emerging viral threats.

By Kelly Bilodeau • Dec. 13, 2023

Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV

Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.

By Alexandra Pecci • Dec. 11, 2023

Discovering the next frontier of blood cancer care

How AstraZeneca is expanding its haematology footprint through the advancement of cutting-edge science in blood cancers.

Dec. 11, 2023

The FDA just approved the first CRISPR drug. Here’s what’s next in gene editing.

A look at the fast-evolving pipeline for gene editing therapies.

By Meagan Parrish • Dec. 8, 2023